東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Target validation in drug discovery

Metcalf, Brian W.

Linked to FindBook

Google Book

Amazon

博客來

Target validation in drug discovery

Record Type:	Electronic resources : Monograph/item
Title/Author:	Target validation in drug discovery/ editors, Brian W. Metcalf and Susan Dillon.{me_controlnum}
other author:	Metcalf, Brian W.
Published:	Amsterdam ;Academic Press, : c2007.,
Description:	xii, 279 p. :ill. ;27 cm.
[NT 15003449]:	Section Contents -- I. Pharmaceutical Biotechnology for Target Validation -- II. Target Validation for Biopharmaceutical Drug Discovery -- III. Validating Targets of Small Molecule Approaches.
Subject:	Drug development. -
Online resource:	http://www.sciencedirect.com/science/book/9780123693938An electronic book accessible through the World Wide Web; click for information
ISBN:	9780123693938

Target validation in drug discovery
Target validation in drug discovery[electronic resource] /editors, Brian W. Metcalf and Susan Dillon.{me_controlnum} - Amsterdam ;Academic Press,c2007. - xii, 279 p. :ill. ;27 cm.

Includes bibliographical references and index.

Section Contents -- I. Pharmaceutical Biotechnology for Target Validation -- II. Target Validation for Biopharmaceutical Drug Discovery -- III. Validating Targets of Small Molecule Approaches.

This work presents a comprehensive contemporary framework for approaching target validation in drug discovery. It begins with a detailed description of new enabling technologies, including aptamers, RNA interference, functional genomics, and proteomics. The next section looks at biologic drug development with in-depth discussion of lessons learned from such well-known cases as Erbitux, Herceptin, and Avastin. Additional targets known as "second generation" drugs, which can be identified when disease pathways are validated by biologics, present new possible small molecule therapeutics and serve as the focus of the final section of the book.

Electronic reproduction.
Amsterdam :
Elsevier Science & Technology,
2007.

Mode of access: World Wide Web.

ISBN: 9780123693938

Source: 113098:113186Elsevier Science & Technologyhttp://www.sciencedirect.comSubjects--Topical Terms:

716904
Drug development.
Index Terms--Genre/Form:

542853
Electronic books.

LC Class. No.: RM301.63 / .T36 2007eb

Dewey Class. No.: 615/.19

National Library of Medicine Call No.: 2006 N-124

Target validation in drug discovery
LDR:02345cmm 2200349Ia 4500 001 1033699
003 OCoLC
005 20110615082928.0
006 m d
007 cr cn|||||||||
008 120420s2007 enka ob 001 0 eng d
020 $a 9780123693938
020 $a 0123693934
029 1 $a NZ1 $b 11778208
035 $a (OCoLC)162130366
035 $a ocn162130366
037 $a 113098:113186 $b Elsevier Science & Technology $n http://www.sciencedirect.com
040 $a OPELS $c OPELS $d OCLCG
049 $a TEFA
050 1 4 $a RM301.63 $b .T36 2007eb
060 1 4 $a 2006 N-124
060 1 4 $a QV 744 $b T185 2007
082 0 4 $a 615/.19 $2 22
245 0 0 $a Target validation in drug discovery $h [electronic resource] / $c editors, Brian W. Metcalf and Susan Dillon.{me_controlnum}
260 $a Amsterdam ; $a Boston : $b Academic Press, $c c2007.
300 $a xii, 279 p. : $b ill. ; $c 27 cm.
504 $a Includes bibliographical references and index.
505 0 $a Section Contents -- I. Pharmaceutical Biotechnology for Target Validation -- II. Target Validation for Biopharmaceutical Drug Discovery -- III. Validating Targets of Small Molecule Approaches.
520 $a This work presents a comprehensive contemporary framework for approaching target validation in drug discovery. It begins with a detailed description of new enabling technologies, including aptamers, RNA interference, functional genomics, and proteomics. The next section looks at biologic drug development with in-depth discussion of lessons learned from such well-known cases as Erbitux, Herceptin, and Avastin. Additional targets known as "second generation" drugs, which can be identified when disease pathways are validated by biologics, present new possible small molecule therapeutics and serve as the focus of the final section of the book.
533 $a Electronic reproduction. $b Amsterdam : $c Elsevier Science & Technology, $d 2007. $n Mode of access: World Wide Web. $n System requirements: Web browser. $n Title from title screen (viewed on July 25, 2007). $n Access may be restricted to users at subscribing institutions.
650 0 $a Drug development. $3 716904
650 0 $a Drugs $x Testing. $3 646233
650 0 $a High throughput screening (Drug development) $3 738793
650 1 2 $a Drug Design. $3 550958
650 2 2 $a Drug Delivery Systems. $3 812174
650 2 2 $a Technology, Pharmaceutical. $3 702084
650 6 $a M�edicaments $x D�eveloppement. $3 1364685
650 6 $a M�edicaments $x Essais cliniques. $3 1364686
650 6 $a Criblage �a haut d�ebit (D�eveloppement des m�edicaments) $3 1364687
655 7 $a Electronic books. $2 lcsh $3 542853
700 1 $a Metcalf, Brian W. $3 1364683
700 1 $a Dillon, Susan, $d 1952- $3 1364684
710 2 $a ScienceDirect (Online service) $3 848416
776 1 $c Original $z 0123693934 $z 9780123693938 $z 9780123693938 $w (DLC) 2006049868 $w (OCoLC)70823305
856 4 0 $3 ScienceDirect $u http://www.sciencedirect.com/science/book/9780123693938 $z An electronic book accessible through the World Wide Web; click for information
994 $a C0 $b TEF